Idexx Laboratories management check
IDXX · Health Care · Health Care Equipment · CEO Jonathan J. Mazelsky
Filings as of
Closest peers in Health Care Equipment
- 153ISRGIntuitive Surgical72
- 158ABTAbbott Laboratories72
- 162SYKStryker Corporation71
- 185IDXXIdexx Laboratories69
- 199BSXBoston Scientific68
- 250RVTYRevvity64
- 284RMDResMed63
- 286GEHCGE HealthCare62
- 322STESteris60
- 353BDXBecton Dickinson58
The seven checks
- WatchTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
3943rdDetail
$100 invested at the start of fiscal 2021 grew to $135, against $148 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
9790thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.94 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch1.4% of net income
What does the CEO cost owners?
$14.6m pay · $1.1bn net income, FY2025
3841stDetail
$14.6m of reported pay in fiscal 2025, against $1.1bn of net income.
- WatchInsiders are selling
Do they own the stock?
6 mo: ▲ $0 bought · ▼ $28.6m sold
——Detail
5 insiders sold $28.6m in the last six months and none bought.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −1.8% a year; flagged above +2%
Stock pay 1.4% of revenue
7264thDetail
Diluted shares changed -1.8% a year over the last three fiscal years. Stock-based pay was 1.4% of revenue in the latest year.
- Watch11 leadership filings in 3 years
Is leadership stable?
11 filings under 8-K 5.02 in 3 years
CEO: Jonathan J. Mazelsky
7046thDetail
CEO in the pay table: Jonathan J. Mazelsky. 11 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed March 27, 2026.
Pay tied most to organic revenue growth
Other key measuresOrganic revenue growthOperating profitEarnings per share (diluted)ROIC
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Jonathan J. Mazelsky | $14.6m | $31.8m | $3.1m | $135 | $148 | $1.1bn |
| 2024 | — | $13.0m | $2.3m | $3.8m | $83 | $129 | $887.9m |
| 2023 | — | $11.5m | $22.7m | $3.3m | $111 | $126 | $845.0m |
| 2022 | — | $9.8m | −$13.8m | $2.8m | $82 | $124 | $679.1m |
| 2021 | — | $9.1m | $28.2m | $2.8m | $132 | $126 | $744.8m |
Insiders and the CEO's stakeSelling
5 insiders sold $28.6m in the last six months and none bought.
Open-market trades by officers and directors since May 21, 2026.
- SoldJonathan Jay MazelskyExecutive Chair of the Board$17.7mNov 4, 2026
- SoldSharon E. UnderbergEVP, GC & Corporate Secretary$6.1mNov 4, 2026
- SoldMichael LaneExecutive Vice President$2.7mNov 4, 2026
- SoldLawrence D KingsleyDirector$1.2mSep 4, 2026
Leadership and governance on file
All 12 filings
- Mar 26, 2026Leadership change8-K 5.02
- Feb 13, 2026Leadership change8-K 5.02
- Jan 13, 2026Leadership change8-K 5.02
- Oct 7, 2025Leadership change8-K 5.02
- Jul 10, 2025Leadership change8-K 5.02
- Feb 14, 2025Leadership change8-K 5.02
- Dec 12, 2024Leadership change8-K 5.02
- Nov 21, 2024Leadership change8-K 5.02
- Nov 12, 2024Leadership change8-K 5.02
- May 10, 2024Leadership change8-K 5.02
- Dec 7, 2023Leadership change8-K 5.02
- Jul 12, 2023Leadership change8-K 5.02
Latest shareholder vote results: May 15, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $3.7bn returned to owners in buybacks and dividends, 88% of net income, and $267.6m of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.2bn | $3.4bn | $3.7bn | $3.9bn | $4.3bn |
| Net income | $744.8m | $679.1m | $845.0m | $887.9m | $1.1bn |
| Stock-based pay | $37.8m | $49.8m | $59.7m | $60.3m | $60.0m |
| Buybacks | $746.8m | $819.7m | $71.9m | $837.0m | $1.2bn |
| Dividends | — | — | — | — | — |
| Diluted shares | 87m | 85m | 84m | 83m | 81m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.